In Vivo Tissue Distribution Studies for ADME in Drug Development
Distribution is a key component of uncovering absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic properties of xenobiotics, investigating the arrival of a drug to its target location and accumulation in various tissues and organs following administration. A drug compound’s distribution can be affected by multiple factors, including plasma protein binding or lysosomal trapping, and needs to be measured accurately and appropriately in accordance with regulatory requirements. Whole-body distribution studies also yield key data for planning first in-human (FIH) mass balance studies in the clinic.
Tissue Distribution Services to Develop Your Drug’s Pharmacokinetic Profile
Quantitative whole-body autoradiography is an in vivo study method in which a rat (or in some cases mouse) is dosed with radiolabeled test article and at successive time points radioactivity is measured in cross-sectioned slides of the whole animal to show distribution over time.
Our Approach to In Vivo ADME
Our in vivo distribution services at the Drug Development Solutions Center (DDSC) use radiolabeled compounds to give whole-body or organ-specific distribution data because radioactivity is a highly sensitive way to quantitatively assess the localization of a parent molecule or its metabolites and required by regulatory agencies prior to clinical trials. Having been founded more than 50 years ago, the DDSC has unparalleled expertise in radioisotope (RI) synthesis and radiolabeled in vivo ADME/PK services to provide drug developers with an experienced team to get the most accurate data with fast turnaround times and carefully planned and executed nonclinical studies.
Studies conducted at Drug Development Solutions Center also meet or exceed standards required by regulatory authorities, including FDA and EMA, just as with our Kansas City campus. While in the United States, there is no method by which an institution can claim certified compliance with Good Laboratory Practice (GLP) standards, the PMDA can grant certification following an inspection that approves a Japanese facility as GLP-compliant in specific practices. The Drug Development Solutions Center has this certification for all bioanalytical services, a critical component of many animal studies. The Center is also certified by AAALAC International for ethical use of animals in research so you can be sure services exceed quality standards required by the FDA upon IND or NDA submission.
By contracting a Drug Development Solutions Center study through SEKISUI XenoTech, we make it easy for North American and European clients to benefit from the years of experience our Tokai team has built. Read more in our blog about how we make it easy to work with the Drug Development Solutions Center for your in vivo nonclinical services.